Stacey Epps, MD
Neurology · Chester, VANPI 1154391571
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 25.5% of the total. Among neurology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,268 payments — averaging $85.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$28K
- Eisai Inc.$23K
- Lilly USA, LLC$21K
- Sanofi$15K
- UCB, Inc.$3K
- Livanova USA, Inc.$2K
- plus $17K from 54 others
What the payments were for
- Consulting fees$14,30013%
- Speaking & faculty fees$64,51759%
- Travel & lodging$5,7425%
- Food & beverage$23,85122%
- Education$4550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AJOVY$22,372
- Leqembi$21,810
- KISUNLA$20,413
- AUBAGIO$14,646
- COPAXONE$4,230
- VNS Therapy$1,424
- ACTIVA$1,192
- ZEPOSIA$496
- ULTOMIRIS$337
- WATCHMAN FLX$290
- NURTEC ODT$238
- XCOPRI$237
- VNS - Sentiva$200
- NOURIANZ$133
- Fintepla$125
- GOCOVRI$123
- AIMOVIG$121
- Mavenclad$121
- VYEPTI$120
- PURIFIED CORTROPHIN GEL$116
How this compares
$108,865 in reported general payments places this provider in the 90th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rebif RebidoseInterferon Beta-1a/Albumin | 24 | $273,752 |
| BriviactBrivaracetam | 133 | $255,317 |
| EpidiolexCannabidiol (Cbd) | 36 | $237,994 |
| XcopriCenobamate | 148 | $206,845 |
| VumerityDiroximel Fumarate | 13 | $115,309 |
| ZeposiaOzanimod Hydrochloride | 12 | $104,170 |
| RytaryCarbidopa/Levodopa | 49 | $70,152 |
| AptiomEslicarbazepine Acetate | 40 | $66,248 |
| Aimovig AutoinjectorErenumab-Aooe | 81 | $65,562 |
| UbrelvyUbrogepant | 34 | $51,530 |
| FycompaPerampanel | 35 | $47,042 |
| Trokendi XrTopiramate | 16 | $40,141 |
| RexultiBrexpiprazole | 21 | $33,371 |
| LamictalLamotrigine | 26 | $32,137 |
| Emgality PenGalcanezumab-Gnlm | 37 | $30,382 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat, Nayzilam | $2,954 | $295,279164 claims |
| SK Life Science, Inc.Xcopri | $1,110 | $206,845148 claims |
| BiogenVumerity | $1,359 | $115,30913 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $517 | $104,17012 claims |
| AbbVieUbrelvy, Namzaric, Qulipta | $1,406 | $97,72879 claims |
| Amneal Pharmaceuticals LLCRytary | $283 | $70,15249 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $438 | $66,24840 claims |
| Eisai Inc.Fycompa | $22,660 | $47,04235 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr | $121 | $40,14116 claims |
| PfizerNurtec Odt, Dilantin | $147 | $33,77143 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $38 | $33,37121 claims |
| Neurelis, Inc.Valtoco | $429 | $25,69417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 neurology providers in Virginia.
Other neurology in Chester
- Ramsey FalconerAlexandria$2M
- Robert ShinCharlottesville$1.7M
- Heidi CraytonVienna$1.5M
- Mark LandrioWinchester$631K
- Catherine HamRichmond$603K
- Jill CramerChristiansburg$598K
- Rahul DaveFairfax$540K
- Daniel HardyRichmond$382K
- Ingrid Loma MillerNorfolk$364K
- Carmen FuentesNorfolk$339K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.